Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T15:41:32.973Z.
Calculation as of: 2026-10-06T15:41:32.973Z.
Quote observation: 2026-10-06T15:39:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7a9a1b17caad0ab37430e79e816a911291535ac0fb348029df9f580b63ef335
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Cadrenal Therapeutics, Inc. Common Stock
Market Cap
$3.42M
Price/OCF Ratio
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO |
|---|---|---|
| Cadrenal Therapeutics, Inc. Common Stock (CVKD) | $3.42M | N/A |
| Eocene Ltd. (EOCN)vs › | $3.42M | N/A |
| Moolec Science S.A. (MLEC)vs › | $3.45M | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.51M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.32M | N/A |
| Nexalin Technology, Inc. (NXL)vs › | $3.54M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.29M | N/A |
| Paranovus Entertainment Technology Ltd. (PAVS)vs › | $3.23M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.21M | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
